Parexel

Parexel launches Connected Journey of newly integrated data-driven services

Monday, June 19, 2017

As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, Parexel International, a global biopharmaceutical services provider, is launching its Connected Journey of data-driven services. This newly integrated network, powered by PAREXEL Analytics capabilities, combines Parexel’s technology, processes and expertise to deliver critical intelligence supporting clinical development and commercialization.  

[Read More]

Hassman Research Institute appoints Dr. Larry Ereshefsky CSO, Early Phase Development

Tuesday, June 6, 2017

Hassman Research Institute (HRI) announced that Dr. Larry Ereshefsky joined the company as chief scientific officer, Early Phase Development. Dr. Ereshefsky brings to HRI more than 40 years of drug discovery and development experience including leadership roles at University of Texas Health Science and Parexel. Dr. Ereshefsky will be responsible for leading HRI’s efforts and advancing the company’s Early Phase Development Division focusing on diseases. He will report to Dr. Howard Hassman, CSO of HRI.

[Read More]

INC Research adds James Featherstone, Janet Baldwin, Nathalie Doize & Alastair MacDonald to team

Friday, March 31, 2017

INC Research Holdings, a global phase I to IV CRO, has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP) and Global Consulting offerings to biopharmaceutical customers worldwide. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the Company’s Global Consulting business to support customers at every stage of their product and portfolio development. INC’s expanded team will help maximize value for sponsors throughout the product lifecycle, from concept to commercialization, by providing consultative and operational expertise in the delivery of real-world evidence. The appointments reinforce INC’s continued focus on providing customers with strategic consulting services along with the right evidence to make the best clinical decisions in this rapidly expanding segment of the clinical research environment.

[Read More]